HC Wainwright set a $9.00 price objective on OpGen (NASDAQ:OPGN) in a research note released on Thursday. The firm currently has a buy rating on the medical research company’s stock.
Other analysts have also issued research reports about the stock. Zacks Investment Research lowered shares of OpGen from a buy rating to a hold rating in a research report on Wednesday, January 10th. ValuEngine upgraded shares of OpGen from a strong sell rating to a sell rating in a research report on Friday, February 2nd.
NASDAQ OPGN opened at $1.91 on Thursday. The company has a current ratio of 1.23, a quick ratio of 1.13 and a debt-to-equity ratio of 0.03. The company has a market cap of $10.10, a P/E ratio of -0.20 and a beta of 1.33. OpGen has a 1 year low of $1.62 and a 1 year high of $31.25.
OpGen (NASDAQ:OPGN) last posted its quarterly earnings results on Thursday, March 15th. The medical research company reported ($1.33) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.38) by $0.05. The business had revenue of $0.99 million for the quarter, compared to analyst estimates of $0.81 million. OpGen had a negative net margin of 479.38% and a negative return on equity of 2,118.30%. equities analysts expect that OpGen will post -2.31 EPS for the current year.
A hedge fund recently raised its stake in OpGen stock. Vanguard Group Inc. boosted its stake in OpGen Inc (NASDAQ:OPGN) by 1.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 342,860 shares of the medical research company’s stock after purchasing an additional 5,500 shares during the period. Vanguard Group Inc. owned about 1.25% of OpGen worth $219,000 at the end of the most recent quarter.
COPYRIGHT VIOLATION WARNING: This article was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/09/opgen-opgn-pt-set-at-9-00-by-hc-wainwright.html.
OpGen, Inc (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms.
Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.